Epiblepharon(n = 55) | Control (n = 60) | t/Z | p | |
---|---|---|---|---|
Gender (Male/Female) | 24/31 | 32/28 | 1.080 | 0.299 |
Age (mean ± SD), yr | 9.82 ± 2.59(6–14)‡ | 10.57 ± 2.75(6–14)‡ | -1.499 | 0.137 |
NIKBUT(mean ± SD), s | 8.49 ± 5.64(2.29–23.31)‡ | 11.09 ± 5.25(2.17–24.03)‡ | -2.555 | 0.012* |
Schirmer test(mean ± SD), mm | 15.07 ± 3.46(8–23)‡ | 15.17 ± 3.83(6–24)‡ | -0.138 | 0.891 |
Meibomian gland expressibility | 0(0,1)†(0–3)‡ | 0(0,0.75)†(0–3)‡ | -0.87 | 0.38 |
Meibum quality | 1(0,2)†(0–6)‡ | 0(0,1)†(0–6)‡ | -2.615 | 0.009* |
Eyelid margin abnormality score | 0(0,1)†(0–2)‡ | 0(0,0.75)†(0–2)‡ | -1.464 | 0.143 |
Total meibomian gland absence score(meibography scores) | 0(0,1)†(0–6)‡ | 0(0,1)†(0–2)‡ | -1.192 | 0.233 |
Morphological changes in Meibomian glands (n, %) | 31(56.36%) | 17(28.33%) | 9.272 | 0.002* |